keyword
MENU ▼
Read by QxMD icon Read
search

rheumatoid arthritis remission

keyword
https://www.readbyqxmd.com/read/28302414/effect-of-panchakarma-and-ayurvedic-treatment-in-postpartum-rheumatoid-arthritis-amavata-a-case-study
#1
Shailesh V Deshpande, Vaishali S Deshpande, Shraddha S Potdar
Dream of a mother is to get involved actively in upbringing of child, which is impeded if she is suffering from painful condition like rheumatoid arthritis (RA) in postpartum phase. It causes physical incapacity and psychological trauma as well. Present case is a patient who developed RA one month after full term delivery by caesarean section. In view of symptoms, she was diagnosed as case of amavata. She received Ayurvedic treatment - Simhanada guggulu, Pratapalankeshwara rasa, Dashamoola katutraya kashaya and combination of Swarnabhupati rasa, Tapyadi loha, Mahavatavidhvansa, Chopachini (Smilax china), Shunthi (Zinziber officinale) and Guduchi (Tinospora cordifolia) for four months and course of kala basti (medicated enema) along with application of medicated oil (Vishagharbha taila abhyanga) and sudation (bashpa sweda) for ten days...
March 13, 2017: Journal of Ayurveda and Integrative Medicine
https://www.readbyqxmd.com/read/28301793/advances-in-rheumatoid-arthritis
#2
Graeme Jones, Peter Nash, Stephen Hall
There are now eight approved biological disease-modifying antirheumatic drugs (bDMARDs), two biosimilars and one targeted synthetic DMARD in Australia with a number of new products and biosimilars in the pipeline. bDMARDs have excellent efficacy, especially when combined with traditional DMARDs, and a well characterised but manageable safety profile. These expanded therapeutic options have revolutionised patient care and made remission (including drug free remission) a realistic goal. Evidence of a "window of opportunity" that changes the long term phenotype of the disease has been well established, so therapy should be commenced as early as possible in the disease process and a shared care model between general practitioner and rheumatologist provides the best outcomes...
March 20, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/28298563/utility-of-dose-frequency-adjustment-in-tocilizumab-administration-for-rheumatoid-arthritis
#3
Shuntaro Saito, Yuko Kaneko, Keisuke Izumi, Tsutomu Takeuchi
OBJECTIVE: To assess the utility of dose frequency adjustment of tocilizumab (TCZ) in rheumatoid arthritis (RA). METHODS: Patients who received TCZ at 3-week (n = 24) or 5-week (n = 61) interval were evaluated. RESULTS: Disease Activity Score at 28 joints based on erythrocyte sedimentation rate in the 3-week group significantly improved after 3 administrations at 3-week intervals (from 4.2 to 2.7, p = 0.001). Forty-five of the patients in the 5-week group (74%) successfully continued 5-week interval administration without disease exacerbation...
March 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28293776/long-term-outcomes-of-treat-to-target-strategy-in-established-rheumatoid-arthritis-a-daily-practice-prospective-cohort-study
#4
Nicole Pamplona Bueno de Andrade, Rafael Mendonça da Silva Chakr, Ricardo Machado Xavier, Daniela Viecceli, Ricardo Henrique Bilycz Correa, Cilomar Martins de Oliveira Filho, Claiton Viegas Brenol
To examine disease activity and physical function after implementation of treat-to-target (T2T) strategy in patients with established rheumatoid arthritis (RA) over a long-term period. Patients with RA were started on a T2T strategy in 2005 and followed through 2014. Patients were seen every 3-4 months until remission/low disease activity was achieved and every 6 months thereafter. Disease activity was measured by the DAS28 and CDAI, and physical function by the HAQ-DI. Results were presented as all observed data, without imputation for missing values...
March 14, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28289873/patient-reported-outcomes-as-predictors-of-remission-in-early-rheumatoid-arthritis-patients-treated-with-tight-control-treat-to-target-approach
#5
Laura Kuusalo, Kari Puolakka, Hannu Kautiainen, Anna Karjalainen, Timo Malmi, Timo Yli-Kerttula, Marjatta Leirisalo-Repo, Vappu Rantalaiho
Identifying prognostic factors for remission in early rheumatoid arthritis (ERA) patients is of key clinical importance. We studied patient-reported outcomes (PROs) as predictors of remission in a clinical trial. We randomized 99 untreated ERA patients to receive remission-targeted treatment with three disease-modifying antirheumatic drugs and prednisolone for 24 months, and infliximab or placebo for the initial 6 months. At baseline, we measured following PROs: eight Short Form 36 questionnaire (SF-36) dimensions, patient's global assessment [PGA, visual analogue scale (VAS)], Health Assessment Questionnaire (HAQ), and pain VAS...
March 13, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28288327/parvovirus-b19-infection-modulates-the-levels-of-cytokines-in-the-plasma-of-rheumatoid-arthritis-patients
#6
Milda Naciute, Diana Mieliauskaite, Rita Rugiene, Gabriele Maciunaite, Mykolas Mauricas, Modra Murovska, Irute Girkontaite
BACKGROUND: Parvovirus B19 (B19V) infection is associated with various autoimmune diseases. We investigated the levels of pro-inflammatory (IFNᵧ, TNFα, IL-2, IL-12) and anti-inflammatory (IL-4, IL-10) cytokines in the plasma of B19V DNA positive (B19(+)) and negative (B19(-)) rheumatoid arthritis (RA) patients in comparison with the control group (healthy persons). METHODS: Blood samples were collected from 118 patients with RA and 49 healthy voluntaries. B19V sequence was determined in whole blood and cell-free plasma DNA by nested PCR...
March 10, 2017: Cytokine
https://www.readbyqxmd.com/read/28285975/monounsaturated-fatty-acids-might-be-key-factors-in-the-mediterranean-diet-that-suppress-rheumatoid-arthritis-disease-activity-the-tomorrow-study
#7
Yoshinari Matsumoto, Yuko Sugioka, Masahiro Tada, Tadashi Okano, Kenji Mamoto, Kentaro Inui, Daiki Habu, Tatsuya Koike
BACKGROUND & AIMS: The Mediterranean diet is reportedly effective in suppressing disease activity in rheumatoid arthritis (RA), but the key elements responsible for this effect remain unknown. The presented study therefore aimed to identify such elements. METHODS: This study included 208 consecutive patients with RA (RA group) and 205 age- and sex-matched healthy volunteers (controls) from the prospective "TOMORROW" cohort study that has been ongoing since 2010 were included in this study...
February 21, 2017: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/28283512/efficacy-of-biological-disease-modifying-antirheumatic-drugs-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-rheumatoid-arthritis
#8
Jackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, Katerina Chatzidionysiou, Josef S Smolen, Désirée van der Heijde, Johannes W Bijlsma, Gerd R Burmester, Maxime Dougados, Marieke Scholte-Voshaar, Ronald van Vollenhoven, Robert Landewé
OBJECTIVES: To update the evidence for the efficacy of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform European League Against Rheumatism (EULAR) Task Force treatment recommendations. METHODS: MEDLINE, EMBASE and Cochrane databases were searched for phase III or IV (or phase II, if these studies were lacking) randomised controlled trials (RCTs) published between January 2013 and February 2016. Abstracts from the American College of Rheumatology and EULAR conferences were obtained...
March 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28282491/biologics-or-tofacitinib-for-people-with-rheumatoid-arthritis-unsuccessfully-treated-with-biologics-a-systematic-review-and-network-meta-analysis
#9
REVIEW
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Lara J Maxwell, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Maria E Suarez-Almazor, Peter Tugwell, George A Wells
BACKGROUND: Biologic disease-modifying anti-rheumatic drugs (DMARDs: referred to as biologics) are effective in treating rheumatoid arthritis (RA), however there are few head-to-head comparison studies. Our systematic review, standard meta-analysis and network meta-analysis (NMA) updates the 2009 Cochrane overview, 'Biologics for rheumatoid arthritis (RA)' and adds new data. This review is focused on biologic or tofacitinib therapy in people with RA who had previously been treated unsuccessfully with biologics...
March 10, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28277345/a-treat-to-target-strategy-preserves-work-capacity-in-a-rheumatoid-arthritis-inception-cohort-treated-with-combination-conventional-dmard-therapy
#10
Mihir D Wechalekar, Stephen Quinn, Susan Lester, Robert G Metcalf, Ella Shanahan, Jennifer G Walker, Malcolm D Smith, Catherine L Hill, E Michael Shanahan, Susanna M Proudman
OBJECTIVES: Quantification of work disability in patients with early rheumatoid arthritis receiving conventional DMARDs according to a treat-to-target strategy. METHODS: Patients received combination conventional DMARDs, escalated to achieve DAS28(ESR) remission and completed an annual work and arthritis questionnaire. Random effect mixed modeling was used to assess associations between average hours worked per week (HWPW), and baseline prognostic factors. HWPW were compared with matched population averages...
March 9, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28269999/baseline-mri-bone-erosion-predicts-the-subsequent-radiographic-progression-in-early-rheumatoid-arthritis-patients-who-achieved-sustained-good-clinical-response
#11
Mami Tamai, Kazuhiko Arima, Yoshikazu Nakashima, Junko Kita, Masataka Umeda, Shoichi Fukui, Ayako Nishino, Takahisa Suzuki, Yoshiro Horai, Akitomo Okada, Tomohiro Koga, Shin-Ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Satoshi Yamasaki, Hideki Nakamura, Tomoki Origuchi, Kiyoshi Aoyagi, Masataka Uetani, Katsumi Eguchi, Atsushi Kawakami
OBJECTIVE: To examine whether magnetic resonance imaging (MRI) findings at baseline predict radiographic progression in early-stage rheumatoid arthritis (RA) patients who have achieved sustained good clinical response. METHODS: This is a sub-analysis from the one-year observational study of Nagasaki University Early Arthritis Cohort. Definition of 'good clinical response' was a decrement of disease activity score (DAS) 28 ≧ 1.2 at three months with achievement of DAS28 remission through 6-12 months...
March 8, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28265470/combination-of-interleukin-27-and-microrna-for-enhancing-expression-of-anti-inflammatory-and-proosteogenic-genes
#12
Manoel Figueiredo Neto, Marxa L Figueiredo
Remission of inflammation has become an achievable goal in inflammatory or rheumatoid arthritis (RA); however, bone erosion continues in many patients. Interleukin- (IL-) 27 regulates immune and bone cell balance and also suppresses activities of several inflammatory cell types in RA. Despite its promise, challenges to clinical translation of IL-27 have been its partial effects in vivo. Due to their ability to modulate plasticity of bone and immune cell differentiation, we examined the potential for several microRNA (miR) candidates in enhancing the effects of IL-27...
2017: Arthritis
https://www.readbyqxmd.com/read/28264816/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-and-biological-disease-modifying-antirheumatic-drugs-2016-update
#13
Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, Jackie Nam, Sofia Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Chris D Buckley, Frank Buttgereit, Vivian Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan Gomez-Reino, Laure Gossec, Jacques-Eric Gottenberg, Johanna M W Hazes, Tom Huizinga, Meghna Jani, Dmitry Karateev, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain McInnes, Eduardo Mysler, Peter Nash, Karel Pavelka, Gyula Poór, Christophe Richez, Piet van Riel, Andrea Rubbert-Roth, Kenneth Saag, Jose da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib)...
March 6, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28258474/impact-of-ultrasonography-on-treatment-decision-in-rheumatoid-arthritis-the-impulsar-study
#14
Cèsar Díaz-Torné, Carme Moragues, Elide Toniolo, Carme Geli, Iván Castellví, Patricia Moya, Ignasi Gich, Josep M Llobet
Ultrasonography (US) has shown to be more sensitive than physical examination for diagnosis and assessment of rheumatoid arthritis (RA). It is also a useful approach for accurate monitoring and intensive treatment adjustment. However, there is limited information concerning the impact of US on therapeutic decision-making in routine daily practice. A single-center cross-sectional study in routine daily practice was conducted to determine the percentage of patients with rheumatoid arthritis (RA) in which treatment decision was modified on the basis of results of musculoskeletal ultrasonography...
March 3, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28256443/cat-scratch-disease-during-etanercept-therapy-in-a-rheumatoid-arthritis-patient
#15
Alberto O Orden, Norma N Nardi, Alicia B Vilaseca, Ana C Colombini, Nora G Barrios, Anahí Vijnovich Barón
Cat scratch disease (CSD) is an infectious disorder caused by Bartonella henselae and characterized by fever and granulomatous lymphadenopathy. Immunosuppression is a risk factor for the development of atypical forms of the disease. We report the case of a 52-year-old woman who presented with fever and bilateral inguinal lymph node enlargement. She did not have apparent contact with animals. The patient was receiving etanercept therapy for rheumatoid arthritis. Lymph node biopsy demonstrated granulomatous lymphadenitis...
February 27, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28255897/bdmard-dose-reduction-in-rheumatoid-arthritis-a-narrative-review-with-systematic-literature-search
#16
REVIEW
Lise M Verhoef, Lieke Tweehuysen, Marlies E Hulscher, Bruno Fautrel, Alfons A den Broeder
INTRODUCTION: Although bDMARDs are effective in the treatment of RA, they are associated with dose-dependent side effects, patient burden, and high costs. Recently, many studies have investigated the possibility of discontinuing or tapering bDMARDs when patients have reached their treatment goal. The aim of this review is to provide a narrative overview of the existing evidence on bDMARD dose reduction and to provide answers to specific dose-reduction-related questions that are of interest to clinicians...
March 2, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28251584/improvements-in-fatigue-in-1536-patients-with-rheumatoid-arthritis-and-correlation-with-other-treatment-outcomes-a-post-hoc-analysis-of-three-randomized-controlled-trials-of-abatacept
#17
Laure Gossec, Souhila Ahdjoudj, Evo Alemao, Vibeke Strand
INTRODUCTION: A post hoc analysis of three randomized controlled trials of abatacept in rheumatoid arthritis (RA) was conducted to explore the effect of abatacept on fatigue in RA and its correlation with other outcomes. METHODS: In this analysis of AGREE (early RA) and AIM and ATTAIN (established RA), changes in baseline fatigue (0-100 mm scale), pain, sleep (AIM and ATTAIN only) and Disease Activity Score (DAS) 28 (C-reactive protein; CRP) were calculated at days 29, 85, and 169...
March 1, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28251392/a-window-of-opportunity-for-abatacept-in-ra-is-disease-duration-an-independent-predictor-of-low-disease-activity-remission-in-clinical-practice
#18
Leslie R Harrold, Heather J Litman, Sean E Connolly, Sheila Kelly, Winnie Hua, Evo Alemao, Lisa Rosenblatt, Sabrina Rebello, Joel M Kremer
The objective of the study was to examine whether disease duration independently predicts treatment response among biologic-naïve patients with rheumatoid arthritis (RA) initiating abatacept in clinical practice. Using the Corrona RA registry (February 2006-January 2015), biologic-naïve patients with RA initiating abatacept with 12-month (±3 months) follow-up and assessment of disease activity (Clinical Disease Activity Index [CDAI]) at initiation and at 12 months were identified. The primary outcome was mean change in CDAI (ΔCDAI) from baseline to 12 months...
March 1, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28247573/review-article-moving-towards-common-therapeutic-goals-in-crohn-s-disease-and-rheumatoid-arthritis
#19
REVIEW
P B Allen, P Olivera, P Emery, D Moulin, J-Y Jouzeau, P Netter, S Danese, B Feagan, W J Sandborn, L Peyrin-Biroulet
BACKGROUND: Crohn's disease (CD) and rheumatoid arthritis are chronic, progressive and disabling conditions that frequently lead to structural tissue damage. Based on strategies originally developed for rheumatoid arthritis, the treatment goal for CD has recently moved from exclusively controlling symptoms to both clinical remission and complete mucosal healing (deep remission), with the final aim of preventing bowel damage and disability. AIM: To review the similarities and differences in treatment goals between CD and rheumatoid arthritis...
March 1, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28243468/baseline-autoantibodies-preferentially-impact-abatacept-efficacy-in-patients-with-rheumatoid-arthritis-who-are-biologic-na%C3%A3-ve-6-month-results-from-a-real-world-international-prospective-study
#20
Rieke Alten, Hubert G Nüßlein, Xavier Mariette, Mauro Galeazzi, Hanns-Martin Lorenz, Alain Cantagrel, Melanie Chartier, Coralie Poncet, Christiane Rauch, Manuela Le Bars
OBJECTIVES: To determine the impact of baseline rheumatoid factor (RF) and anticyclic citrullinated peptide (anti-CCP) status on the clinical efficacy of intravenous abatacept in biologic-naïve patients with rheumatoid arthritis (RA) enrolled in the real-world ACTION study. METHODS: Clinical outcomes (European League Against Rheumatism (EULAR) response, mean Clinical Disease Activity Index (CDAI) and Boolean remission) at 6 months were compared by baseline RF and anti-CCP status...
2017: RMD Open
keyword
keyword
52663
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"